



AMENDMENT TRANSMITTAL LETTER

Docket No.
030682.0001-US01

Application No.
10/632,428-Conf. #4377

Filing Date
August 1, 2003

Examiner
D. R. Rao

Art Unit
1624

Applicant(s): David Bebbington et al.

Invention: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	72	- 168 =	0	x 50.00	0.00
Independent Claims	2	- 3 =	0	x 210.00	0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify): Information Disclosure Statement Fee					180.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					180.00

☒ Large Entity

☐ Small Entity

☒ No additional fee is required for this amendment.

☐ Please charge Deposit Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.

☒ A check in the amount of \$ 180.00 to cover the filing fee is enclosed.

☐ Payment by credit card. Form PTO-2038 is attached.

☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0740
as described below. A duplicate copy of this sheet is enclosed.

☒ Credit any overpayment.

☒ Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.

Andrea G. Reister
Attorney/Agent Reg. No.: 36,253
COVINGTON & BURLING LLP
1201 Pennsylvania Avenue, N.W.
Washington, DC 20004-2401
(202) 662-5141

Dated: July 2, 2008



AMENDMENT TRANSMITTAL LETTER

Docket No.
030682.0001-US01

Application No.
10/632,428-Conf. #4377

Filing Date
August 1, 2003

Examiner
D. R. Rao

Art Unit
1624

Applicant(s): David Bebbington et al.

Invention: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	72	- 168 =	0	x 50.00	0.00
Independent Claims	2	- 3 =	0	x 210.00	0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify): Information Disclosure Statement Fee					180.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					180.00

☒ Large Entity

☐ Small Entity

☒ No additional fee is required for this amendment.

☐ Please charge Deposit Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.

☒ A check in the amount of \$ 180.00 to cover the filing fee is enclosed.

☐ Payment by credit card. Form PTO-2038 is attached.

☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0740
as described below. A duplicate copy of this sheet is enclosed.

☒ Credit any overpayment.

☒ Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.

Andrea G. Reister

Dated: July 2, 2008

Andrea G. Reister
Attorney/Agent Reg. No.: 36,253
COVINGTON & BURLING LLP
1201 Pennsylvania Avenue, N.W.
Washington, DC 20004-2401
(202) 662-5141



Docket No.: 030682.0001-US01
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
David Bebbington et al.

Application No.: 10/632,428

Art Unit: 1624

Filed: August 1, 2003

Examiner: Deepak Rao

For: PYRAZOLE COMPOUNDS USEFUL AS
PROTEIN KINASE INHIBITORS

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated April 2, 2008, Applicants submit the following amendments and remarks pursuant to 37 C.F.R. § 1.111.

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 11 of this paper.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in this paper or documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to Deposit Account No. 50-0740.